The expansion of CD14+CD16+ monocytes has been reported in a variety of inflammatory disorders including rheumatoid arthritis (RA) and inflammatory bowel disease (IBD) (11, 12, 31), implying an important role of these cells in disease pathogenesis. Here, FCGR3A is linked to inflammatory bowel disease.